• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Bracco's ProHance wins new indications

Article

Bracco Diagnostics has received new indications from the Foodand Drug Administration for head and neck and pediatric CNS imagingfor its ProHance MRI agent. ProHance has been approved for usein children two years of age and older for MRI of the brain,

Bracco Diagnostics has received new indications from the Foodand Drug Administration for head and neck and pediatric CNS imagingfor its ProHance MRI agent. ProHance has been approved for usein children two years of age and older for MRI of the brain, spineand associated tissues at a dose of 0.1 mmol/kg. It is also nowindicated for the visualization of extracranial and extraspinalpathology of the head and neck region in adults at a dose of 0.1mmol/kg. Bracco Diagnostics is based in Princeton, NJ, and wasformed when Italy's Bracco bought Squibb Diagnostics.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.